Amgen Inc. which can be found using ticker (AMGN) now have 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $380.00 and $170.00 and has a mean share price target at $307.59. (at the time of writing). Given that the stocks previous close was at $278.49 this would imply there is now a potential upside of 10.4%. Also worth taking note is the 50 day moving average now sits at $297.21 and the 200 day MA is $262.62. The company has a market capitalization of 148.70B. The stock price for the company is currently $277.46 USD
The potential market cap would be $164,233,652,501 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 22.21, revenue per share of $52.69 and a 6.29% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
